You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 信达生物(1801.HK)涨超5% 获港股通昨日净买入13.93亿港元
格隆汇 09-08 09:36
格隆汇9月8日丨信达生物(1801.HK)高开高走,现报60.6港元,涨5.39%,暂成交3090万港元,最新总市值848亿港元。据“医药魔方”消息,9月5日信达生物提交的1类新药IBI319临床申请获得CDE受理,这是信达生物申报临床的第5款双抗。此外,信达生物获纳入港股通昨日生效,据格隆汇APP显示,港股通昨日净买入信达生物13.93亿港元,居当日净买额榜首。美银证券近日发研报指,信达生物旗下达伯舒(信迪利单抗注射液)在最大癌症适应症中的发展势头强劲;且基于信达生物与礼来公司及Coherus的合作,将其目标价上调至65港元,维持“买入”评级,看好其药物时间表及国际策略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account